Skip to main content
Erschienen in: Hepatology International 3/2008

Open Access 01.09.2008 | Case Report

Spontaneous bacterial peritonitis from Salmonella: an unusual bacterium with unusual presentation

verfasst von: Harshal Rajekar, Chun-Tao Wai, Kang-Hoe Lee, Sin-Yew Wong, Kai-Chah Tan

Erschienen in: Hepatology International | Ausgabe 3/2008

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Spontaneous bacterial peritonitis (SBP) is a common cause of morbidity and mortality in patients with advanced cirrhosis and portal hypertension. While gram-negative rods and Enterococcus species are the common offending organisms, Salmonella has also been recognized as a rare and atypical offending organism. Atypical features of Salmonella SBP include both its occurrence in cirrhotic patients with immunosuppressive state and its lack of typical neutroascitic response. Diagnosis is often delayed as it requires confirmation from ascitic fluid culture. We report a case of Salmonella SBP occurring in a patient with decompensated cryptogenic cirrhosis with concurrent low-grade non-Hodgkin lymphoma and prior treatment with rituximab. Physicians should be aware of the atypical presentation, especially in cirrhotic patients who are immunosuppressed.

Introduction

Spontaneous bacterial peritonitis (SBP) due to Salmonella is uncommon in cirrhotic patients with ascites, and it is often associated with an immunosuppressed state and often presents without typical signs or symptoms of SBP [1, 2]. We report a case of SBP due to group B Salmonella in a patient with decompensated cryptogenic cirrhosis and portal hypertension.

Case

A 61-year-old female Arab patient was referred to our center for management of decompensated cryptogenic liver cirrhosis. She has type II diabetes mellitus since adolescence and hypertension of 5 years’ duration. She was also diagnosed with B-cell follicular non-Hodgkin lymphoma (NHL), stage IIIA, involving gastric mucosa and abdominal lymph nodes, 8 months ago. She was treated with rituximab (anti-CD20 monoclonal antibodies) and dexamethasone. However, she developed grade IV hepatic encephalopathy after three cycles of rituximab and chemotherapy was stopped.
Since the onset of encephalopathy, she started complaining of worsening ascites and lethargy, and had two more episodes of grade IV hepatic encephalopathy. By February 2008, she was referred to our center for evaluation for live donor liver transplantation (LDLT). She had no history of variceal bleeding or SBP and was not on prophylactic antibiotics. Initial physical examination showed moderate ascites and bilateral ankle edema, with normal chest and heart examinations. Blood tests showed normal creatinine and electrolytes, bilirubin 82 uM, albumin 26 g/l, alanine transaminase 22 U/l, aspartate transaminase 43 U/l, and alkaline phosphatase 73 U/l. Complete blood cell count showed slightly low hemoglobin at 11.3 g/dl, low platelets at 65,000/mm3, and normal white cells at 5,050/mm3. INR was elevated at 1.31. Computed tomographic (CT) scan revealed cirrhotic liver, splenomegaly, moderate ascites, and small, subcentimeter retroperitoneal lymphadenopathy. No gallstones were seen on CT or ultrasound scan. Positron emission tomography CT scan did not reveal any fluorodeoxyglucose-avid lesions to suggest active lymphoma, and ascitic fluid cytology was negative for lymphoma cells.
While she was undergoing evaluation for LDLT, she complained of acute onset of generalized abdominal pain. There was no fever, diarrhea, vomiting, or urinary symptoms. Clinically, she was afebrile and did not have tachycardia, but there was right-sided abdominal tenderness. A diagnosis of SBP was suspected and the patient was admitted for diagnostic paracentesis and empiric antibiotics therapy. Urinalysis and urine culture were unremarkable. Initial ascitic fluid analysis results showed a leukocyte count of 110/mm3, majority being lymphocytes, with lactate dehydrogenase, protein, and albumin at 54 U/l, 11 g/l, and 5 g/l, respectively. Her serum ascitic albumin gradient was 21 g/l, consistent with significant portal hypertension. However, 2 days later, ascitic fluid culture showed presence of group B Salmonella, which was sensitive to both ceftriaxone and ciprofloxacin. She was treated with an intravenous dose of ceftriaxone for a week followed by an oral dose of ciprofloxacin. Intravenous albumin infusion was also given concurrently to prevent renal impairment. Subsequent blood and stool cultures did not show growth of any organisms. She recovered well from the infection, with resolution of abdominal pain and tenderness; she underwent LDLT 2 weeks after diagnosis of Salmonella SBP. During laparotomy, no intra-abdominal lymphadenopathy was noted and explant liver did not show any evidence of active lymphoma. She has been recovering well from the transplant and remained well at her last follow-up 6 weeks posttransplant.

Discussion

SBP is a common complication of patients with decompensated cirrhosis, occurring in 10% to 30% of cirrhotic patients with ascites, with a mortality of up to 30%. Standard investigation includes ascitic fluid analysis for cell count analysis, biochemical analysis, and cultures. Third generation cephalosporins with intravenous albumin infusion are the standard treatment. Definitive diagnosis does not require a positive culture because an ascitic fluid neutrophil count of more than 250/mm3 is sufficient for diagnosis, as culture results often take a minimum of 48 h to be available [3, 4].
Common offending organisms in SBP are Klebsiella pneumoniae, Escherichia coli, and Enterococcus species [5, 6]. Non-typhoidal Salmonella is a rare cause of SBP. Previous case series reported various immune-compromised states, such as AIDS and non-hepatic cancer, as risk factors for Salmonella SBP [1, 2]. In our patient, her immunosuppressive state could be related to her prior administration of rituximab, an anti-CD20 monoclonal antibody. Depletion of peripheral B lymphocytes, important for humoral response to bacterial antigens, has been shown to last for up to 2 years after its administration [7, 8]. In addition, her underlying low-grade NHL and diabetes mellitus may have also contributed to her immunosuppressive state.
Salmonella SBP is an unusual form of SBP as it has also been reported to be asymptomatic, with no overt systemic signs of infection. There may be little biochemical evidence, or neutroascitic response in ascitic fluid analysis, and the diagnosis often requires confirmation on ascitic fluid culture [3]. As seen in our patient, her only symptom was abdominal pain and initial ascitic fluid analysis did not reveal any neutroascitic reaction or elevation of lactate dehydrogenase and confirmation of SBP was made only 48 h later when ascitic culture results returned.
In summary, we reported a case of a cirrhotic patient who was immunosuppressed from follicular NHL and prior use of rituximab, presenting atypically for SBP that was subsequently diagnosed as Salmonella SBP. Physicians should be aware of this atypical presentation and routine ascitic fluid culture should be performed in patients suspected of having SBP, particularly in cirrhotic patients with an immunosuppressive state.
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://​creativecommons.​org/​licenses/​by-nc/​2.​0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt bestellen und 100 € sparen!

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Jetzt bestellen und 100 € sparen!

Literatur
1.
Zurück zum Zitat de la Fuente-Aguado J, Bordón J, Esteban AR, Aguilar A, Moreno JA. Spontaneous non-typhoidal Salmonella peritonitis in patients with serious underlying disorders. Infection 1999;27:224–227CrossRef de la Fuente-Aguado J, Bordón J, Esteban AR, Aguilar A, Moreno JA. Spontaneous non-typhoidal Salmonella peritonitis in patients with serious underlying disorders. Infection 1999;27:224–227CrossRef
2.
Zurück zum Zitat Reddy KR, Chan JC, Smiley D, Jeffers LJ, Schiff ER. Spontaneous group B Salmonella enteritidis peritonitis in cirrhotic ascites and acquired immune deficiency syndrome. Am J Gastroenterol 1988;83:882–884PubMed Reddy KR, Chan JC, Smiley D, Jeffers LJ, Schiff ER. Spontaneous group B Salmonella enteritidis peritonitis in cirrhotic ascites and acquired immune deficiency syndrome. Am J Gastroenterol 1988;83:882–884PubMed
3.
Zurück zum Zitat Runyon BA. Management of adult patients with cirrhosis. Hepatology 2004;29:1–16CrossRef Runyon BA. Management of adult patients with cirrhosis. Hepatology 2004;29:1–16CrossRef
4.
Zurück zum Zitat Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142–153PubMedCrossRef Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142–153PubMedCrossRef
5.
Zurück zum Zitat Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140–148PubMedCrossRef Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140–148PubMedCrossRef
6.
Zurück zum Zitat Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049–1056PubMedCrossRef Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049–1056PubMedCrossRef
7.
Zurück zum Zitat Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–2581PubMedCrossRef Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–2581PubMedCrossRef
8.
Zurück zum Zitat Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119–1128PubMedCrossRef Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119–1128PubMedCrossRef
Metadaten
Titel
Spontaneous bacterial peritonitis from Salmonella: an unusual bacterium with unusual presentation
verfasst von
Harshal Rajekar
Chun-Tao Wai
Kang-Hoe Lee
Sin-Yew Wong
Kai-Chah Tan
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 3/2008
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-008-9087-9

Weitere Artikel der Ausgabe 3/2008

Hepatology International 3/2008 Zur Ausgabe

Erratum

Errata

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.